Aajami Zahra, Kebriaeezadeh Abbas, Nikfar Shekoufeh
Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Pharmaceutical Management and Economics Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Iran J Neurol. 2019 Jan 5;18(1):7-12.
Alzheimer's disease (AD) affects a large number of adults annually all around the world. The monetary cost of this disorder is huge. This study aims to estimate the cost of AD in Iran by considering stages of disease. A cross-sectional study was designed from July to December 2017 on 300 AD cases who referred to the Iran Alzheimer's Association, Tehran, Iran. To calculate costs at different stages of disease, patients were assigned into three groups, based on the Mini-Mental State Exam (MMSE) score. A list of medicines' prices and health care service costs were prepared. Health care services' cost was acquired from the book of "Relative value units of health care services in Iran" and the price of medicines was extracted from "Iran's medicine triple prices list". Patients' medical records and face to face interview with their caregivers were used for data collection. The perspective of present research was societal. Annually, per person cost of AD in mild, moderate, and severe stages of disease were 434 United States dollars (USD), 1313 USD, and 2480 USD, respectively. Direct non-medical costs (DNMC) had the greatest share of total costs (near half of the whole costs) including 263 USD, 641 USD, and 1257 USD for mild, moderate, and severe stages, respectively. The cost of AD in Iran is lower than the average cost of dementia in upper middle-income countries. In all stages, the biggest part of the cost is associated with patient care and nursing services because patients suffering from AD usually require specialized cares.
阿尔茨海默病（AD）每年在全球影响大量成年人。这种疾病的金钱成本巨大。本研究旨在通过考虑疾病阶段来估算伊朗的AD成本。2017年7月至12月对300例转诊至伊朗阿尔茨海默病协会（位于伊朗德黑兰）的AD患者进行了一项横断面研究。为了计算疾病不同阶段的成本，根据简易精神状态检查表（MMSE）评分将患者分为三组。准备了药品价格和医疗服务成本清单。医疗服务成本取自《伊朗医疗服务相对价值单位》一书，药品价格从《伊朗药品三重价格清单》中提取。通过患者病历以及与他们的护理人员进行面对面访谈来收集数据。本研究的视角是社会层面的。每年，AD在疾病轻度、中度和重度阶段的人均成本分别为434美元、1313美元和2480美元。直接非医疗成本（DNMC）在总成本中占比最大（接近总成本的一半），轻度、中度和重度阶段分别为263美元、641美元和1257美元。伊朗的AD成本低于中高收入国家痴呆症的平均成本。在所有阶段，成本的最大部分与患者护理和护理服务相关，因为AD患者通常需要专门护理。
